Cargando…

Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study

INTRODUCTION: Primary ovarian carcinoids are extremely rare ovarian tumors, and there is limited data available on their clinical characteristics and survival outcomes. MATERIAL AND METHODS: We conducted a historical cohort study of 56 patients to investigate their clinical characteristics. The over...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Shujun, Sun, Jianan, Sui, Xiaolong, Zhang, Shuaizhi, Qi, YuanBao, Ma, Yuanxu, Li, Sijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333664/
https://www.ncbi.nlm.nih.gov/pubmed/37059424
http://dx.doi.org/10.1111/aogs.14578
_version_ 1785070712326717440
author Kong, Shujun
Sun, Jianan
Sui, Xiaolong
Zhang, Shuaizhi
Qi, YuanBao
Ma, Yuanxu
Li, Sijian
author_facet Kong, Shujun
Sun, Jianan
Sui, Xiaolong
Zhang, Shuaizhi
Qi, YuanBao
Ma, Yuanxu
Li, Sijian
author_sort Kong, Shujun
collection PubMed
description INTRODUCTION: Primary ovarian carcinoids are extremely rare ovarian tumors, and there is limited data available on their clinical characteristics and survival outcomes. MATERIAL AND METHODS: We conducted a historical cohort study of 56 patients to investigate their clinical characteristics. The overall survival, disease‐specific survival, recurrence‐free survival, and potential prognostic factors of these patients were also evaluated. RESULTS: The median age of these patients was 42.0 years (range: 20–71). The average mass and carcinoid size was 7.3 and 0.4 cm, respectively. Elevated tumor marker levels and ascites were observed in 15 and 10 patients, respectively. In 98.2% of the patients, tumors were confined to the ovary, while only one had metastatic disease. Surgery was the mainstay therapy: 37.5% of the patients underwent unilateral salpingo‐oophorectomy, 25.0% underwent hysterectomy with bilateral salpingo‐oophorectomy, 21.4% underwent ovarian cystectomy, 10.7% underwent comprehensive staging surgery, and 5.4% underwent bilateral salpingo‐oophorectomy. Appendectomy and lymphadenectomy were performed in eight and five patients, respectively, but none showed tumor involvement. Chemotherapy was the only adjuvant treatment utilized, and was administered in four patients. Pathological analysis showed that strumal carcinoid was the most predominant subtype, occurring in 66.1% of the patients. The Ki‐67 index was reported in 39 patients, 30 of which had an index of no more than 3%, with a maximum of only 5%. Only one relapse occurred after the initial treatment, and that patient experienced recurrences on two occasions, maintaining stable disease after surgery and octreotide therapy. After a median follow‐up of 3.6 years, 96.4% of the patients achieved no evidence of disease, while 3.6% were alive with the disease. The 5‐year recurrence‐free survival rate was 97.9% and no death occurred. No risk factors for recurrence‐free survival, overall survival, or disease‐specific survival were identified. CONCLUSIONS: The Ki‐67 indices were extremely low and prognoses were excellent in patients with primary ovarian carcinoids. Conservative surgery, especially unilateral salpingo‐oophorectomy, is preferred. Individualized adjuvant therapy may be considered for patients with metastatic diseases.
format Online
Article
Text
id pubmed-10333664
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103336642023-07-12 Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study Kong, Shujun Sun, Jianan Sui, Xiaolong Zhang, Shuaizhi Qi, YuanBao Ma, Yuanxu Li, Sijian Acta Obstet Gynecol Scand Oncology INTRODUCTION: Primary ovarian carcinoids are extremely rare ovarian tumors, and there is limited data available on their clinical characteristics and survival outcomes. MATERIAL AND METHODS: We conducted a historical cohort study of 56 patients to investigate their clinical characteristics. The overall survival, disease‐specific survival, recurrence‐free survival, and potential prognostic factors of these patients were also evaluated. RESULTS: The median age of these patients was 42.0 years (range: 20–71). The average mass and carcinoid size was 7.3 and 0.4 cm, respectively. Elevated tumor marker levels and ascites were observed in 15 and 10 patients, respectively. In 98.2% of the patients, tumors were confined to the ovary, while only one had metastatic disease. Surgery was the mainstay therapy: 37.5% of the patients underwent unilateral salpingo‐oophorectomy, 25.0% underwent hysterectomy with bilateral salpingo‐oophorectomy, 21.4% underwent ovarian cystectomy, 10.7% underwent comprehensive staging surgery, and 5.4% underwent bilateral salpingo‐oophorectomy. Appendectomy and lymphadenectomy were performed in eight and five patients, respectively, but none showed tumor involvement. Chemotherapy was the only adjuvant treatment utilized, and was administered in four patients. Pathological analysis showed that strumal carcinoid was the most predominant subtype, occurring in 66.1% of the patients. The Ki‐67 index was reported in 39 patients, 30 of which had an index of no more than 3%, with a maximum of only 5%. Only one relapse occurred after the initial treatment, and that patient experienced recurrences on two occasions, maintaining stable disease after surgery and octreotide therapy. After a median follow‐up of 3.6 years, 96.4% of the patients achieved no evidence of disease, while 3.6% were alive with the disease. The 5‐year recurrence‐free survival rate was 97.9% and no death occurred. No risk factors for recurrence‐free survival, overall survival, or disease‐specific survival were identified. CONCLUSIONS: The Ki‐67 indices were extremely low and prognoses were excellent in patients with primary ovarian carcinoids. Conservative surgery, especially unilateral salpingo‐oophorectomy, is preferred. Individualized adjuvant therapy may be considered for patients with metastatic diseases. John Wiley and Sons Inc. 2023-04-14 /pmc/articles/PMC10333664/ /pubmed/37059424 http://dx.doi.org/10.1111/aogs.14578 Text en © 2023 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Oncology
Kong, Shujun
Sun, Jianan
Sui, Xiaolong
Zhang, Shuaizhi
Qi, YuanBao
Ma, Yuanxu
Li, Sijian
Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study
title Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study
title_full Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study
title_fullStr Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study
title_full_unstemmed Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study
title_short Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study
title_sort clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: a historical cohort study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333664/
https://www.ncbi.nlm.nih.gov/pubmed/37059424
http://dx.doi.org/10.1111/aogs.14578
work_keys_str_mv AT kongshujun clinicalcharacteristicsandsurvivaloutcomesinpatientswithprimaryovariancarcinoidahistoricalcohortstudy
AT sunjianan clinicalcharacteristicsandsurvivaloutcomesinpatientswithprimaryovariancarcinoidahistoricalcohortstudy
AT suixiaolong clinicalcharacteristicsandsurvivaloutcomesinpatientswithprimaryovariancarcinoidahistoricalcohortstudy
AT zhangshuaizhi clinicalcharacteristicsandsurvivaloutcomesinpatientswithprimaryovariancarcinoidahistoricalcohortstudy
AT qiyuanbao clinicalcharacteristicsandsurvivaloutcomesinpatientswithprimaryovariancarcinoidahistoricalcohortstudy
AT mayuanxu clinicalcharacteristicsandsurvivaloutcomesinpatientswithprimaryovariancarcinoidahistoricalcohortstudy
AT lisijian clinicalcharacteristicsandsurvivaloutcomesinpatientswithprimaryovariancarcinoidahistoricalcohortstudy